Fungus
Onychomycosis
search
Onychomycosis
, Tinea Unguium
See Also
Nail Disorder
Paronychia
Definitions
Onychomycosis
Chronic fungal infection affecting the
Toenail
or
Fingernail
Epidemiology
Prevalence
Gene
ral population: 10%
Prevalence
(worldwide)
Age under 20 years: 3%
Prevalence
(U.S.)
Age over 60 years: 28%
Prevalence
(U.S.)
Most common
Nail Disorder
(accounts for 50% of
Nail Disorder
s)
Rarely occurs in children unless predisposing factors
Immunosuppression
(e.g.
AIDS
)
Extensive fungal skin involvement
Family History
of Onychomycosis
Pathophysiology
Causes
Dermatophytes (70%)
Non-dermatophyte molds and yeasts (30%)
Mixed infection in up to 39%
Person to person transmission
Toenail
s are more commonly affected than
Fingernail
s
Decreased blood supply and slower growth (compared with
Fingernail
s)
Dark, moist environment
Risk Factors
Older age (especially over age 60-70 years)
Peripheral Arterial Disease
Decreased immune function
Slowed
Nail Growth
Prolonged fungal exposures
Tinea Pedis
or other fungal infection
Swimming pools, locker rooms or other use of shared bathing areas
Psoriasis
Nail deformity
Recurrent nail
Trauma
Hyperhidrosis
Tobacco Abuse
Obesity
Immunodeficiency
Diabetes Mellitus
(>1.9 fold increased risk)
HIV Infection
(15-40%
Prevalence
)
Types
Distal Lateral Subungual (most common)
Affects distal and lateral
Toenail
s and
Fingernail
s (esp. first and fifth
Toenail
s)
Starts distally (at
Hyponychium
) and spreads into nail plate and nail bed
Associated with hyperkeratosis with secondary
Onycholysis
and ultimately
Dystrophic Nail
s with yellow or brown discoloration
Acquired through break in skin at nail undersurface (e.g. seocndary to
Tinea Pedis
,
Paronychia
)
Most common etiology: Trichophyton rubrum
However any of the fungal organisms may be causative
Superficial or superficial white Onychomycosis (10% of cases, esp. children)
Most common etiology: Trichophyton mentagrophytes
Typically white (but sometimes black) powdery patches forming horizontal nail lines
Endonyx Subungual (rare subtype of distal subungual)
Etiologies
Trichophyton soudanense
Trichophyton violaceum
Direct infection of full nail thickness without affecting nail bed
May affect entire
Toenail
s
Starts as opaque, well demarcated milky-white spots
Spots coalesce to involve entire nail
Associated findings
Lamellar splitting and nail indentations
No hyperkeratosis or
Onycholysis
Proximal Subungual (uncommon)
Most common etiology: Trichophyton rubrum
Affects proximal
Fingernail
s and
Toenail
s
Fungi invade proximal nail fold to enter nail
Hyperkeratosis and debris form under proximal nail
Results in
Onycholysis
that spreads gradually from proximal to distal nail
Predisposing factors
Immunocompromised
status (e.g.
HIV Infection
or
AIDS
)
Local
Trauma
may also result in similar presentation
Candida Onychomycosis (rare)
Associated with
Chronic Paronychia
(Candida)
More common in
Immunocompromised
state
Total dystrophic Onychomycosis
Total nail plate destruction from above types (especially distal subungual)
Diffusely thickened and yellow nail
Nail crumbles and is friable
Associated with long-term infection that thickens the nail and ultimately destroys the nail structure
Long-standing, progressive distal lateral subungual Onychomycosis
Long standing, progressive proximal subungual Onychomycosis (esp.
Immunocompromised
)
Mixed-Pattern Onychomycosis
Combination of multiple subtypes
Secondary Onychomycosis
Superinfected secondary condition (esp.
Psoriasis
)
Signs
Nail plate changes
Discoloration
White or yellow
Green in cases of
Pseudomonas
superinfection
Deformed (hypertrophic or hyperkeratotic)
Opacification
Subungual debris
Onycholysis
Brittle nails that crumble with minimal force
Foul nail odor
Distribution based on type (see above)
Labs
Obtaining Nail specimens
Nail preparation
Wipe the nail with 70%
Isopropyl Alcohol
Use sterile nail clipper to obtain 8-10 nail shards if possible (improves
Test Sensitivity
)
Obtain subungual material with 2 mm curette or #15 blade
Nail drill may be used for proximal nail location
Techniques for specific nail types
Distal subungual Onychomycosis
Clip nail short
Apply curette to nail bed near cuticle for sample
Also scrape underside of nail plate
White superficial Onychomycosis
Scrape nail plate surface white area for sample
Proximal superficial Onychomycosis
Pare nail plate near lunula
Curette sample from infected nail bed
Candidal Onychomycosis
Labs
Miscellaneous
Potassium Hydroxide
(10-20% KOH): Subungual debris scraping
Test Sensitivity
: 56-80%
Test Specificity
: 72-95%
Periodic acid-Schiff Stain (PAS Stain)
Test Sensitivity
: 82%
Performed with nail biopsy (see below)
Nail
Fungal Culture
Test Sensitivity
: 23-85%
Test Specificity
: 82-99%
Nail Biopsy: Periodic acid schiff stain (effective, but expensive and not widely available)
Test Sensitivity
: 81-96%
Test Specificity
: 72-89%
Fungal PCR
Test Sensitivity
: 83%
Test Specificity
: 84%
Results in 3 days where available
Expensive and not widely available
References
Wilsmann-Theis (2011) J Eur Acad Dermatol Venereol 25(2): 235-7 [PubMed]
Differential Diagnosis
See
Dystrophic Nail
Only 50% of
Dystrophic Nail
s are Onychomycosis
Infection
Candida
Paronychia
(
Chronic Paronychia
)
Bacteria
l
Paronychia
(
Acute Paronychia
)
Periungual wart
Associated with
Onycholysis
and longitudinal grooves
Herpetic Whitlow
(
Herpes Simplex Virus
)
Bleeding or purpuric nail lesions
Trauma
Ingrown Toenail
Local nail
Trauma
(e.g. tight footwear, manicures or pedicures)
Onychodystrophy
Associated with
Onycholysis
, periungual keratosis
Skin conditions
Psoriasis
Affects nails in >50% of cases
Associated with
Nail Pitting
,
Onycholysis
, brown-red patches, subungual hyperkeratosis
Lichen Planus
(especially
Fingernail
s)
Affects nails in >10% of cases
Associated with longitudinal grooves, nail thinning,
Pterygium
on the dorsal surface
Variant: Twenty-
Nail Dystrophy
(children)
Contact Dermatitis
or other chronic dermatitis
Associated with
Nail Pitting
,
Beau Lines
(transverse grooves)
Nail bed tumor
Fibroma or
Dermatofibroma
(benign)
Smooth, firm
Nodule
s that develop at nail folds
Subungual Melanoma
Nail affected in up to 7% of cases
Associated with Brown-yellow
Nail Discoloration
, subungual hyperkeratosis, onychorrhexis
Bowen Disease
(
Squamous Cell Carcinoma
)
Nail affected in 8% of cases
Associated with
Paronychia
, poor
Nail Growth
,
Onycholysis
Miscellaneous causes
Yellow Nail Syndrome
Trachyonychia
Associated with longitudinal ridges, brittle nails,
Nail Pitting
Affects all nails
References
Allevato (2010) Clin Dermatol 28(2): 164-77 [PubMed]
Management
Gene
ral Measures
Keep feet dry
Wear cotton socks and change 2-3 times per day
Wear shoes that are breathable
Reduce fungus exposure
Wear foot protection in shared showers (locker room) and other public areas
Treat
Tinea Pedis
Optimize chronic disease management
Diabetes Mellitus
Tobacco Cessation
Anticipatory Guidance
Fingernail
s require 3-6 months to fully regrow
Toenail
s require up to 18 months to fully regrow
Antifungal Medication
s
Systemic
Antifungal
s (esp.
Terbinafine
) are considered preferred treatment for Onychomycosis
Consider
Topical Antifungal
to treat periungual fungus or in mild cases (see indications below)
Consider longer
Antifungal
course in some patients
Slow
Nail Growth
Extensive nail plate involvement
Diminished blood supply
Peripheral Vascular Disease
Diabetes Mellitus
Surgical Management
Nail trimming and
Debridement
may be used as an adjunct to systemic and
Topical Antifungal
s
Consider nail removal in severe
Onycholysis
Management
Systemic
Antifungal
Agents and Laser
Indications
Immunocompromised
patients
Secondary infection risk (e.g.
Diabetes Mellitus
)
Foot Pain
Cosmesis (warn regarding imperfect cure rates, and nails may remain dystrophic)
Background
Confirm Onychomycosis and not a mimic on differential diagnosis
Onychomycosis is visually misdiagnosed in up to 50% of patients with
Dystrophic Nail
s
Cure rates are listed in clinical cure (appearance) and mycologic cure (culture/microscopy)
Monitoring of liver transaminases is typically baseline and at 4-6 weeks after starting therapy
Terbinafine
(
Lamisil
)
Indications
First-line therapy due to best efficacy and low cost ($4 per month)
No further
Liver Function Test
s needed if baseline
Liver Function Test
s are normal and no systemic symptoms
See
Terbinafine
for
Drug Interaction
s
Dosing: Daily
See
Terbinafine
for dosing and lab monitoring
Child 10 to 20 kg: 62.5 mg once daily
Child 20 to 40 kg: 125 mg once daily
Adult (and child >40 kg): 250 mg once daily
Dosing:
Pulse
d 12-4
Take daily dosing for 12 weeks on, then 12 weeks off, then 4 weeks on
Highest effectiveness, safety and cost of
Terbinafine
regimens in adults (as well as compared with other agents)
Gupta (2023) Br J Dermatol 189(1): 12-22 [PubMed]
Dosing:
Pulse
d 4-4
Take daily dosing for 4 weeks on, then 4 weeks off, then 4 weeks on
Yadav (2015) Indian J Dermatol Venereol Leprol 81(4):363-9 [PubMed]
Duration
Fingernail
s: 6 weeks
Toenail
s: 12 weeks
Most effective oral
Antifungal
agent for treatment of Onychomycosis
Cure rate
Clinical cure: 75% for
Fingernail
s, 38-76% for
Toenail
s
Clinical relapse: 21% in severe cases
Mycologic cure: 76% with negative culture/microscopy
Mycologic relapse: 23% in severe cases
Itraconazole
(
Sporanox
)
Indications
Onychomycosis due to yeast or non-dermatophytes
See
Itraconazole
for dosing and lab monitoring
Fingernail
s
Daily (continuous): 200 mg daily for 6 weeks
Monthly (pulsed): 200 mg twice daily for one week per month for 2-3 months
Toenail
s
Daily (continuous): 200 mg daily for 12 weeks
Monthly (pulsed): 200 mg twice daily for one week per month for 3-4 months
Cure rate
Clinical cure: 70%
Mycologic cure: 69% with negative culture/microscopy (63% if pulse dosing)
High recurrence rates in severe cases (roughly double
Terbinafine
relapse rate)
Mycologic relapse: 53% (contrast with 23% for
Terbinafine
)
Clinical relapse: 48% (contrast with 21% for
Terbinafine
)
Nd:YAG Laser (Neodymium:yttrium-aluminum-garnet laser)
Indicated in Onychomycosis refractory to systemic agents
Efficacy based only on small studies
61% complete mycologic cure rates after 1-3 treatments at 4-6 week intervals
Kimura (2012) J Drugs Dermatol 11(4): 496-504 [PubMed]
References
De Doncker (1996) Arch Dermatol 132:34-41 [PubMed]
Evans (1999) BMJ 318:1031-5 [PubMed]
Faergernann (1995) J Am Acad Dermatol 32: 750-3 [PubMed]
Gupta (2004) Br J Dermatol 150(3): 537-44 [PubMed]
Management
Less Effective Systemic Agents (generally avoid these for Onychomycosis)
Background
Avoid systemic agents listed here (
Griseofulvin
and
Fluconazole
) for Onychomycosis
Agents listed above (
Terbinafine
and
Itraconazole
) have better efficicacy
Griseofulvin
has greater toxicity risk
Fluconazole
(
Diflucan
)
See
Fluconazole
for dosing and lab monitoring
Dosing
Child: 3-6 mg/kg (up to 150 to 300 mg) once weekly for at least 6 months, until entire nail grows out
Adult: 150 mg once weekly for at least 6 months, until entire nail grows out
Cure rate
Clinical cure: 76% for
Fingernail
s, 31% for
Toenail
s
Mycologic cure: 48% with negative culture/microscopy
References
Gupta (2004) Br J Dermatol 150(3): 537-44 [PubMed]
Scher (1998) J Am Acad Dermatol 38:S77-S86 [PubMed]
Griseofulvin
Rare use due to long treatment duration, low cure rights, increased adverse effects
Low cure rates (30-45%) even when taken for up to 6-12 months at 500-1000 mg daily
Faergernann (1995) J Am Acad Dermatol 32: 750-3 [PubMed]
Management
Topical Agents
Indications for Topical Agents
No more than 3 nails affected
Superficial Onychomycosis
Distal lateral subungual Onychomycosis
Affecting <50% of nail plate surface area
Nail Matrix not involved
Prevention of Onychomycosis recurrence or reinfection
See prognosis for protocol below
Avoid topical agents in moderate to severe Onychomycosis
Minimally if at all effective in significant Onychomycosis
Local irritation is common
If a topical agent is used,
Ciclopirox
(
Penlac
) would be preferred in combination with
Debridement
Ciclopirox
(
Penlac
) 8% nail lacquer
Applied daily for 48 weeks for
Toenail
s, 24 weeks for
Fingernail
s
Gene
ric
Ciclopirox
costs $300 per year ($20/bottle) to treat two nails in 2020
Marginally better than
Placebo
Clinical cure rate 5-6% for
Fingernail
s, 6-9% for
Toenail
s (up to 36% with negative culture/microscopy)
When used with
Debridement
may offer up to 77% mycotic cure rate (negative culture/microscopy)
References
Gupta (2000) J Am Acad Dermatol 43(4 suppl) S70-80 [PubMed]
Malay (2009) J Foot Ankle Surg 48(3): 294-308 [PubMed]
Efinaconazole (Jublia) 10% nail lacquer
Topical agent for Onychomycosis
Appears more effective than
Penlac
Less effective than oral agents
Apply 2 drops daily to a great toe nail (or 1 drop for other nails) daily for 48 weeks
Very expensive ($650 for 4 ml - treats one great
Toenail
per 6 weeks)
May cost $9000 for a year course for multiple nails
Clinical cure rate: 15 to 18%
(2014) Presc Lett 21(8): 47
Tavaborole (Kerydin) 5%
Similarly very expensive ($430/bottle)
Topical Antifungal
with low efficacy
Applied daily for 48 weeks
Cosmetic procedures
Laser Therapy (e.g. PinPointe)
Treats only the cosmetic appearance of the nail (not the fungal infection)
Argentina pichinchensis (snakeroot extract)
Similar efficacy to
Ciclopirox
(
Penlac
)
Romero-Cerecero (2008) Planta Med 74(12): 1430-35 [PubMed]
Dual-wavelength near-infrared laser (Noveon)
Marginal benefits by study with atypical measures of clinical cure and 30% mycologic cure
Landsman (2010) J Am Podiatr Med Assoc 100(3):166-77 [PubMed]
OTC Nail Lacquers (e.g. Fungi-Nail)
Over-the-counter (otc)
Antifungal
agents that treat periungual fungus, but do not penetrate the nail to treat Onychomycosis
Vicks VapoRub
No proven efficacy in Onychomycosis
Tea Tree Oil
No proven efficacy in Onychomycosis
Prognosis
Recurrence rate after effective treatment: 20-25% within 2 years (up to 50% in some studies)
Decreased recurrence with
Topical Antifungal
applied twice weekly after treatment
Shemer (2017) Dermatol Ther 30(5): e12545 +PMID:28856784 [PubMed]
Factors associated with recurrence
Age >70 years old
Nail
Trauma
Diabetes Mellitus
Complications
Cellulitis
in older patients
Diabetic Foot Ulcer
References
(2013) Presc Lett 20(5): 28
Gilbert (1999) Sanford Guide to Antimicrobials
Andrews (2008) Am Fam Physician 77(10): 1415-20 [PubMed]
Crawford (2002) Arch Dermatol 138: 811-6 [PubMed]
Crissey (1998) Postgrad Med 103(2):191-205 [PubMed]
Ely (2014) Am Fam Physician 90(10): 702-10 [PubMed]
Frazier (2021) Am Fam Physician 104(4): 359-67 [PubMed]
Gupta (1997) Dermatol Clin 15(1):121-35 [PubMed]
Harrell (2000) J Am Board Fam Pract 13:268-73 [PubMed]
Hay (2011) J Am Acad Dermatol 65(6): 1219-27 [PubMed]
Rodgers (2001) Am Fam Physician 63(4):663-72 [PubMed]
Scher (1999) J Am Acad Dermatol 40:S21-6 [PubMed]
Weinberg (2003) J Am Acad Dermatol 49:193-7 [PubMed]
Westerberg (2013) Am Fam Physician 88(11): 762-70 [PubMed]
Type your search phrase here